AptarGroup

Global Pharmaceutical Packaging Market Outlook & Forecast Report 2022-2027 - Increasing Virtual Consultations Is Anticipating The Growth Of Aluminium-Based Drug Packaging - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Packaging, Manufacturing, Amcor, Transport, PET, PP, RFID, R, AptarGroup, Plastics industry, Oxygen, International Paper, COVID-19, Plastic, RTS, LMIC, CCL Industries, Carbon dioxide, Health, QR, Vaccine, Conditional sentence, Greenhouse, CR, WestRock, CO2, Growth, Blister, Prevalence, HDPE, ACG, Monkeypox, Fine chemical, Pharmaceutical industry, Recycling, Medical device, Borosilicate glass

In Europe, the key players in the global biodegradable pharmaceutical packaging market include Gerresheimer, Berry Global, International Paper, and Amcor.

Key Points: 
  • In Europe, the key players in the global biodegradable pharmaceutical packaging market include Gerresheimer, Berry Global, International Paper, and Amcor.
  • Moreover, pharmaceutical packaging for biologics, sterile packaging, smart packaging, patient focus packaging, cleanroom expansion, and others are anticipated to drive the global pharmaceutical packaging market in the long term.
  • Pharmaceutical companies account for the highest market share of 48.18% in the global pharmaceutical packaging market by end-user segment.
  • The highest revenue share of pharma companies is because pharmaceutical companies are the primary source for the pharmaceutical packaging market.

Aptar to Present at 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023

Retrieved on: 
Wednesday, December 21, 2022
Packaging, Cosmetics, Engineering, Retail, Health, Manufacturing, Pharmaceutical, Conference, NYSE, AptarGroup, CFO, ATR, Pharmaceutical industry, Management

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced their participation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced their participation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023.
  • Stephan Tanda, President and CEO, will present at 12:45 p.m. Eastern Standard Time.
  • Bob Kuhn, Executive Vice President and CFO and Gael Touya, President Aptar Pharma, will also be available.

Aptar in Top 15 of America’s Most Responsible Companies 2023 by Newsweek

Retrieved on: 
Thursday, December 15, 2022
Other Consumer, Other Manufacturing, Packaging, Other Retail, Manufacturing, Health, Consumer, Pharmaceutical, Retail, World Business Council for Sustainable Development, Life, Statista, Sustainability reporting, KPI, NYSE, SHERO, Health, Partnership, Science, Le Point, CSR, MacArthur Foundation, ATR, Ellen, Engineering, Corporate social responsibility, Social responsibility, Most, Culture, Female, Beauty, Sustainable development, GRI, Food, Patient, Renewable energy, AptarGroup, Newsweek

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, has been named one of Americas Most Responsible Companies 2023 by Newsweek and is ranked #15 out of 500 U.S. companies.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, has been named one of Americas Most Responsible Companies 2023 by Newsweek and is ranked #15 out of 500 U.S. companies.
  • View the full release here: https://www.businesswire.com/news/home/20221215006024/en/
    We are extremely proud to be recognized by Newsweek and Statista for the fourth consecutive year.
  • Newsweek, in partnership with Statista one of the largest statistics database companies worldwide evaluated Americas Most Responsible Companies based on the 2,000 largest public companies by revenue in the U.S. and publicly available CSR (Corporate Social Responsibility) performance data in the environmental, social and corporate governance categories.
  • Newsweeks full list of Americas Most Responsible Companies 2023 can be found here .

Aptar Announces the Realignment of Two of its Business Reporting Segments

Retrieved on: 
Monday, December 12, 2022
Research, Medical Devices, Packaging, Health Technology, Manufacturing, Other Health, Pharmaceutical, Health, Science, Other Science, Security (finance), Food, AptarGroup, Analysis, Beauty, Financial condition report, Patient, Science, ATR, Drug Quality and Security Act, NYSE, Cosmetics, Form, Growth, Engineering, Marketing, Health, Result

Aptars two renamed reporting segments will be Aptar Closures and Aptar Beauty.

Key Points: 
  • Aptars two renamed reporting segments will be Aptar Closures and Aptar Beauty.
  • Aptar Closures will focus specifically on leveraging the closures platform with an aim of broadening the markets that Aptar serves with these technologies.
  • Aptar will continue to have three reporting segments: Aptar Pharma, Aptar Beauty and Aptar Closures.
  • This press release contains forward-looking statements, including the potential benefits of the realignment of our business reporting segments.

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics

Retrieved on: 
Thursday, November 3, 2022
Infection, Skin, Science, Nasal cavity, FDA, AptarGroup, Inhalation, Nasal administration, Annual report, White House, Freezing, University, Technology, Company, Beauty, Refrigeration, GLOBE, UDS, Vaccination, Waste, Toxic Substances Control Act of 1976, CEO, Prognosis, Lung, UT, Nose, Vaccine, Health, Drug development, Patient, Nasal mucosa, Research, Bureau of Oceans and International Environmental and Scientific Affairs, Particle size, Government, Powder, COVID-19, Food, Immunization, Therapy, Safety, University of Texas at Austin, Engineering, NASDAQ, Risk, TFF, Absorption, Area studies, Immunity, Thin film, Pharmaceutical industry

FORT WORTH, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced a collaboration with Aptar Pharma, a global leader in drug delivery and active material science solutions and services, aimed at developing and testing the administration of dry powder vaccines utilizing TFF Pharmaceutical’s Thin Film Freezing technology and Aptar Pharma’s proprietary intranasal Unidose (UDS) Powder Nasal Spray System.

Key Points: 
  • The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous or intramuscular-based delivery.
  • These aspects of nasal delivery could expand vaccine availability to larger populations in regions and countries with limited refrigeration infrastructure.
  • During the Vaccines Summit-2022, which took place from October 11 to 13, 2022 in Washington DC, U.S., Aptar Pharma presented research findings from their collaboration with TFF Pharmaceuticals.
  • Intranasal dry powder vaccines could be a true game changer for people around the world.

Aptar Again Named a Global Top Female-Friendly Company by Forbes

Retrieved on: 
Wednesday, November 2, 2022
Professional Services, Packaging, Consumer, Women, Manufacturing, Human Resources, Security (finance), AptarGroup, Securities Exchange Act of 1934, Culture, Mentorship, Health, Leadership, U.S. Securities and Exchange Commission, Board, NYSE, Director, Result, Securities Act of 1933, Statista, Financial condition report, ATR, Form, Beauty, Forbes, Workplace, Food, Woman, Patient, Multimedia, Engineering, Drug Quality and Security Act, Forward-looking statement, Female, Analysis, Science, Management

For this ranking, Forbes partnered with Statista to identify global companies leading the way in supporting women in the workplace and world at large.

Key Points: 
  • For this ranking, Forbes partnered with Statista to identify global companies leading the way in supporting women in the workplace and world at large.
  • This award reflects our diverse, equitable and inclusive culture, which has allowed us to retain and attract female talent.
  • Marcia Thomas, Director, Global Diversity & Inclusion, shared, This year we continued to make great strides on our diversity, equity and inclusion journey.
  • Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services.

Aptar and Chiesi Sign Digital Health Contract to bring Best-in-Class Disease Management Platform for Patients with Asthma and COPD

Retrieved on: 
Tuesday, October 18, 2022
Technology, Biotechnology, Packaging, Health, Manufacturing, Pharmaceutical, Professional Services, Other Science, Research, Software, Managed Care, General Health, Data Analytics, Science, Quality of life, Fourth Estate Public Benefit Corporation, Administration, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Communication, Disease, COPD, NYSE, Patient, Result, Asthma, Financial condition report, ATR, Security (finance), Securities Act of 1933, B Corporation (certification), Digital health, Partnership, Technology, Degenerative disease, Software, Benefit corporation, Analysis, Respiratory disease, Form, Securities Exchange Act of 1934, Ageing, Environment, Forward-looking statement, Disease management, Chronic obstructive pulmonary disease, Health, Data analysis, Solution, Fine chemical, Pharmaceutical industry, AptarGroup, Chiesi Farmaceutici

Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic partnership with the Chiesi Group, the international research-focused biopharmaceutical and healthcare group, to bring to market a disease management platform for asthma and chronic obstructive pulmonary disease (COPD).

Key Points: 
  • Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic partnership with the Chiesi Group, the international research-focused biopharmaceutical and healthcare group, to bring to market a disease management platform for asthma and chronic obstructive pulmonary disease (COPD).
  • Aptar Digital Health is a division of Aptar Pharma, part of Aptar (NYSE:ATR).
  • Respiratory illnesses such as asthma and COPD represent an enormous burden on healthcare systems in Europe.
  • Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions.

Aptar Declares Quarterly Dividend

Retrieved on: 
Thursday, October 13, 2022
Packaging, Health, Manufacturing, Other Health, Other Manufacturing, Pharmaceutical, AptarGroup, U.S. Securities and Exchange Commission, Interest, Drug Quality and Security Act, Investor, Science, Central Time, NYSE, Securities Exchange Act of 1934, Patient, Result, Financial condition report, ATR, Security (finance), Securities Act of 1933, Analysis, Health, Form, Food, Forward-looking statement, Beauty, Engineering

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today declared a quarterly cash dividend of $0.38 per share.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today declared a quarterly cash dividend of $0.38 per share.
  • As previously announced, Aptar will hold a conference call on Friday, October 28, 2022 at 8:00 a.m. Central Time to discuss the Companys third quarter results for 2022.
  • Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services.
  • Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries.

Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma and Fluidda

Retrieved on: 
Thursday, September 22, 2022
Software, Research, Pharmaceutical, Data Management, Technology, Medical Devices, Packaging, Clinical Trials, Science, Biotechnology, FDA, Health, Manufacturing, Securities Exchange Act of 1934, HRCT, Bureau of Oceans and International Environmental and Scientific Affairs, ANDA, Chronic obstructive pulmonary disease, U.S. FDA, Computational fluid dynamics, NYSE, FDA, Drug Quality and Security Act, Beauty, ATR, Food and Drug Administration, PBPK, Asthma, Abbreviated New Drug Application, Securities Act of 1933, Forward-looking statement, U.S. Securities and Exchange Commission, Program, Patient, Analysis, CEO, Technology, Financial condition report, Result, Diagnosis, Food, Form, Security (finance), COPD, Multimedia, FRI, Functional, CFD, GWP, Pharmaceutical industry, Generic drug, Medical imaging, Fine chemical, Science, Analytic, AptarGroup

Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging.

Key Points: 
  • Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging.
  • A company would have to spend several years to achieve the current combined expertise and experience of Nanopharm and Fluidda.
  • The collaboration between Nanopharm and Fluidda has the potential to revolutionize this arduous regulatory pathway, stated Dr. Jag Shur, Vice President, Science & Technology at Nanopharm.
  • Guillaume Brouet, Vice President, Analytical, Regulatory and Scientific Affairs at Aptar Pharma, commented, Aptar Pharma is delighted to collaborate with Fluidda on this important development, which reinforces our mission to help customers derisk and accelerate their drug product development programs.

Aptar Appoints Matthew L. Trerotola to its Board of Directors

Retrieved on: 
Monday, September 12, 2022
Packaging, Health, Manufacturing, Other Health, Other Manufacturing, Pharmaceutical, Health, Communication, Engineering, McKinsey & Company, NYSE, Director, Chemical engineering, Beauty, ATR, Company, University, Growth, Advanced Materials, Harvard Business School, European Conservatives and Reformists Group Executive, DuPont, Patient, CEO, MBA, Electronics, Board of directors, Food, Board, Multimedia, Executive, Management, Science, Danaher Corporation, AptarGroup

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Matt Trerotola has joined its Board of Directors.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Matt Trerotola has joined its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20220912005805/en/
    Matt Trerotola Joins Aptars Board of Directors (Photo: Aptar)
    Matt has served as the President and Chief Executive Officer for Enovis Corporation (formerly Colfax), an innovation-driven medical technology company, since 2015.
  • We are pleased to welcome Matt Trerotola to our Board of Directors.
  • Matt Trerotola said, I am excited to join the Board of Aptar, a company that improves the lives of millions of people around the world through its technologies and services.